Discussing the results from Edgewise Therapeutics ARCH study of EDG-5506, a myofiber type II myosin inhibitor for patients with Becker Muscular Dystrophy (BMD).

Executed on:Feb 15, 2024 1:15 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Duke UniversityAssistant Professor in the Department of Pediatrics, Division of Neurology at Duke University. Co-Director of Duke Children's Neuromuscular Program
Manages 20 patients with Becker Muscular Dystrophy
Research interest in Duchenne Muscular Dystrophy, spinal muscular dystrophy, and other rare forms of neuromuscular disease including Becker Muscular Dystrophy.

Interview Goal

Reviewing the standard of care for Becker Muscular Dystrophy and the results from the ARCH trial, an open-label, single center study assessing EDG-5506's safety and pharmacokinetics in BMD patients. 

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.